Urinary leukotrienes and thromboxanes - New prognostic biomarker of recurring restenosis in patients with lower limb ischemia?

Aim: Endovascular treatment (EVT) is less successful in patients with recurrent restenosis. Even though the role of eicosanoids in atherosclerosis is well-known, their influence on restenosis after endovascular treatment has not been studied yet. We, therefore, wanted to establish prognostic features of urinary leukotrienes E4 (uLTE4) and thromboxane B2 (uTXB2) in occurrence of restenosis.